

Board of Directors:	Ognian Donev, PhD Vessela Stoeva Alexandar Tchaoushev Bissera Lazarova Ivan Badinski
Executive Director:	Ognian Donev, PhD
Procurators:	Simeon Donev
Finance Director:	Boris Borisov
Preparer:	Lyudmila Bondzhova
Head of Legal Department:	Alexandar Yotov
Address of Management:	Sofia 16, Iliensko Shosse Str.
Lawyers:	Ventsislav Stoev
Servicing Banks:	KBS Bank DSK Bank EAD Eurobank and FG Bulgaria AD ING Bank N.V. UniCredit AD Citibank N.A. Municipal Bank AD
Auditor:	Baker Tilly Klitou and Partners OOD

SOPHARMA GROUP
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
for the three-month period ending 31 March 2023

	Notes	1 January - 31 March 2023 BGN'000	1 January - 31 March 2022 BGN'000
Revenue from contracts with customers	3	467 204	397 570
Other operating income / (losses), net	4	2 661	2 129
Changes in inventories of finished goods and work in progress		2 476	4 591
Raw materials and consumables used	5	(23 693)	(23 596)
Hired services expense	6	(19 596)	(14 766)
Employee benefits expense	7	(40 781)	(34 774)
Depreciation and amortization expense	14,15	(13 399)	(12 811)
Carrying amount of goods sold		(341 199)	(295 144)
Other operating expenses	8	(1 595)	(1 372)
Profit from operations		32 078	21 827
Finance income	10	879	1 072
Finance costs	11	(2 730)	(1 897)
Finance income/(costs), net		(1 851)	(825)
Profit from associates and joint ventures, net	12	6 992	4 026
Gain/(Loss) on acquisition and disposal of and from subsidiaries		-	-
Profit from acquisition and disposal of subsidiaries		-	-
Profit before tax		37 219	25 028
Income tax expense		(3 576)	(2 468)
Net profit for the period		33 643	22 560
Other components of comprehensive income:			
<i>Items that will not be reclassified to profit or loss:</i>			
Net change in the fair value of other long-term equity investments	13	(1 957)	156
		(1 957)	156
<i>Items that may be reclassified to profit or loss:</i>			
Exchange differences on translating foreign operations		(409)	(1 039)
Share of other comprehensive income of associates		1 743	(1 228)
		1 334	(2 267)
Other comprehensive income for the period, net of tax	13	(623)	(2 111)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		33 020	20 449
Net profit for the year attributable to:			
Equity holders of the parent		32 254	20 681
Non-controlling interests		1 389	1 879
Total comprehensive income for the year attributable to:			
Equity holders of the parent		31 631	18 580
Non-controlling interests		1 389	1 869
Basic net profit per share	BGN	0,27	0,17
Net earnings per diluted share	BGN	0,26	0,17

The notes on pages 5 to 141 are an integral part of the present consolidated financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Preparer:

Lyudmila Bondzhova

SOPHARMA GROUP
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
for the three-month period ending 31 March 2023

	Notes	31 March 2023 BGN'000	31 December 2022 BGN'000
ASSETS			
Non-current assets			
Property, plant and equipment	14	374 545	376 407
Intangible assets	15	47 175	48 151
Goodwill	15	3 499	3 522
Investment properties	16	10 568	10 568
Investments in associated and joint ventures	17	171 600	162 844
Other long - term equity investments	18	3 438	4 778
Long-term receivables from related parties	19	70 012	67 471
Other long-term receivables	20	7 590	5 694
Deferred tax assets		1 911	2 052
		690 338	681 487
Current assets			
Inventories	21	296 002	278 583
Commercial receivables	22	253 961	224 442
Receivables from related parties	23	13 079	12 909
Other short-term receivables and assets	24	38 692	36 702
Cash and cash equivalents	25	19 639	19 855
		621 373	572 491
TOTAL ASSETS		1 311 711	1 253 978
EQUITY AND LIABILITIES			
Equity attributable to equity holders of the parent			
Share capital		134 798	134 798
Reserves		46 743	47 503
Other capital components (reserve for issued warrants)		12 488	12 488
Retained earnings		542 260	509 869
	26	736 289	704 658
Non-controlling interests		13 365	11 976
TOTAL EQUITY	26	749 654	716 634
LIABILITIES			
Non-current liabilities			
Long-term bank loans	27	29 439	27 759
Deferred tax liabilities		5 839	6 397
Long-term liabilities to related parties	28	25 496	24 494
Long-term payables to personnel	29	6 618	6 541
Lease liabilities	30	51 123	52 058
Government grants	31	6 046	6 155
Other non-current liabilities	32	6 594	6 594
		131 155	129 998
Current liabilities			
Short-term bank loans	33	162 999	158 355
Short-term part of long-term bank loans	27	9 022	9 758
Trade payables	34	193 667	175 567
Payables to related parties	35	5 297	4 904
Factoring agreement liabilities	36	1 807	1 875
Short-term part of leasing liabilities	30	12 512	12 874
Payables to personnel and social security	37	22 251	21 780
Tax payables	38	8 861	8 436
Other current liabilities	39	14 486	13 797
		430 902	407 346
TOTAL LIABILITIES		562 057	537 344
TOTAL EQUITY AND LIABILITIES		1 311 711	1 253 978

The notes on pages 5 to 141 are an integral part of the present consolidated financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Preparer:

Lyudmila Bondzhova

CONSOLIDATED STATEMENT OF CASH FLOWS

for the three-month period ending 31 March 2023

	Notes	1 January - 31 March 2023 BGN'000	1 January - 31 March 2022 BGN'000
Cash flows from operating activities			
Revenue from contracts with customers		505 136	441 710
Payments to suppliers		(433 645)	(374 971)
Payments for wages and social security		(38 827)	(33 383)
Taxes paid (profit tax excluded)		(18 987)	(17 303)
Taxes refunded (profit tax excluded)		1 561	2 315
Income taxes paid		(133)	(63)
Interest and bank charges paid on working capital loans		(1 579)	(1 484)
Exchange rate differences, net		(298)	(556)
Other proceeds/(payments), net		(519)	(216)
Net cash flows used in operating activities		12 709	16 049
Cash flows from investing activities			
Purchases of property, plant and equipment		(5 248)	(3 770)
Proceeds from sales of property, plant and equipment		170	873
Purchases of intangible assets		(1 778)	(1 148)
Purchases of capital investments		(657)	(341)
Proceeds from sale of capital investments		40	426
Proceeds from release of subsidiaries, net of cash provided		-	200
Purchases of investments in associated companies and joint ventures		-	(692)
Proceeds from sale of investments in associates and joint ventures		-	-
Loans granted to related parties		(2 450)	(1 500)
Loans granted to other parties		(4 696)	-
Received interest on loans and deposits		65	25
Net cash flows used in investing activities		(14 554)	(5 927)
Cash flows from financial activities			
Proceeds from short-term bank loans (including increases in overdrafts)		22 768	-
Repayment of short-term bank loans (including decreases in overdrafts)		(13 754)	(34 204)
Proceeds from long-term bank loans		-	11 356
Repayment of long-term bank loans		(3 414)	(6 520)
Proceeds under factoring agreement		700	6 500
Interest paid under factoring agreement		(23)	(15)
Interest and charges paid under investment purpose loans		(110)	(93)
Lease payments		(4 540)	(4 504)
Dividends paid		(2)	(4)
Government grants		4	4
Proceeds / (payments), net, related to other capital components (warrants)		-	101
Net cash flows from financial activities		1 629	(27 379)
Net increase/(decrease) in cash and cash equivalents		(216)	(17 257)
Cash and cash equivalents at 1 January		19 851	37 717
Cash and cash equivalents at 31 March	25	19 635	20 460

The notes on pages 5 to 141 are an integral part of the present consolidated financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Preparer:

Lyudmila Bondzhova

SOPHARMA GROUP

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
for the year ending on 31 March 2023

Notes	Attributable to owners of the parent company								Non-controlling		Total	
	Share capital	Treasury shares	Statutory reserves	Revaluation reserve - property, plant and equipment	Reserve from financial assets at fair value through other comprehensive income	Translation of foreign operations reserve	Other capital components (reserve for issued warrants)	Retained earnings	Total			
	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	
Balance at 1 January 2022	26	134 798	(50 284)	66 201	36 788	1 644	682	12 512	444 634	646 975	11 893	658 868
Changes in equity for 2022												
Effect of treasury shares acquisition		-	-	-	-	-	-	-	-	-	-	-
Effects of sold rights under issued warrants		-	-	-	-	-	-	(2)	103	101	-	101
Distribution of profit for:		-	-	-	-	-	-	-	-	-	-	-
* statutory reserves		-	-	-	-	-	-	-	-	-	-	-
* dividends		-	-	-	-	-	-	-	-	-	-	-
Effects assumed by non-controlling interests on:		-	-	-	-	-	-	-	-	-	-	-
* acquisition/(disposal) of subsidiaries		-	-	-	-	-	-	-	-	-	-	-
* distribution of dividends		-	-	-	-	-	-	-	-	-	-	-
* issue of capital in subsidiaries		-	-	-	-	-	-	-	-	-	-	-
* increase in the interest in subsidiaries		-	-	-	-	-	-	-	-	-	-	-
* decrease in the interest in subsidiaries		-	-	-	-	-	-	-	-	-	-	-
Total comprehensive income for the year, including:		-	-	-	-	156	(2 257)	-	20 681	18 580	1 869	20 449
* net profit for the year		-	-	-	-	-	-	-	20 681	20 681	1 879	22 560
* other comprehensive income, net of taxes		-	-	-	-	156	(2 257)	-	-	(2 101)	(10)	(2 111)
Transfer to retained earnings		-	-	-	(150)	(34)	-	-	184	-	-	-
Balance at 31 March 2022	26	134 798	(50 284)	66 201	36 638	1 766	(1 575)	12 510	465 602	665 656	13 762	679 418
Balance at 1 January 2023		134 798	(52 203)	68 628	35 263	560	(4 745)	12 488	509 869	704 658	11 976	716 634
Changes in equity for 2023												
Effect of treasury shares		-	-	-	-	-	-	-	-	-	-	-
Effects of rights sold under issued warrants		-	-	-	-	-	-	-	-	-	-	-
Profit distribution for:		-	-	-	-	-	-	-	-	-	-	-
* legal reserves		-	-	-	-	-	-	-	-	-	-	-
* dividends		-	-	-	-	-	-	-	-	-	-	-
Effects assumed by non-controlling interests on:		-	-	-	-	-	-	-	-	-	-	-
* acquisition/(disposal) of subsidiaries		-	-	-	-	-	-	-	-	-	-	-
* distribution of dividends		-	-	-	-	-	-	-	-	-	-	-
* issue of capital in subsidiaries		-	-	-	-	-	-	-	-	-	-	-
* increase in the interest in subsidiaries		-	-	-	-	-	-	-	-	-	-	-
* decrease in the interest in subsidiaries		-	-	-	-	-	-	-	-	-	-	-
Total comprehensive income for the year, incl:		-	-	-	-	(1 957)	1 334	-	32 254	31 631	1 389	33 020
* net profit for the year		-	-	-	-	-	-	-	32 254	32 254	1 389	33 643
* other comprehensive income, net of taxes		-	-	-	-	(1 957)	1 334	-	-	(623)	-	(623)
Transfer to retained earnings		-	-	-	(139)	2	-	-	137	-	-	-
Balance at 31 March 2023	26	134 798	(52 203)	68 628	35 124	(1 395)	(3 411)	12 488	542 260	736 289	13 365	749 654

The notes on pages 5 to 141 are an integral part of the present consolidated financial statement.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Preparer:

Lyudmila Bondzhova